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Abstract 
Electrical properties of cells determine most of the cellular functions, particularly ones which 
occur in the cell’s membrane. Manipulation of these electrical properties may provide a powerful 
electrotherapy option for the treatment of cancer as cancerous cells have been shown to be more 
electronegative than normal proliferating cells. Previously, we used an electrical impedance sensing 
system (EIS) to explore the responses of cancerous SKOV3 cells and normal HUVEC cells to low 
intensity (<2 V/cm) AC electric fields, determining that the optimal frequency for SKOV3 prolif-
eration arrest was 200 kHz, without harming the non-cancerous HUVECs. In this study, to de-
termine if these effects are cell type dependant, human breast adenocarcinoma cells (MCF7) were 
subjected to a range of frequencies (50 kHz–2 MHz) similar to the previously tested SKOV3. For 
the MCF7, an optimal frequency of 100 kHz was determined using the EIS, indicating a higher 
sensitivity towards the applied field. Further experiments specifically targeting the two types of 
cancer cells using HER2 antibody functionalized gold nanoparticles (HER2-AuNPs) were per-
formed to determine if enhanced electric field strength can be induced via the application of 
nanoparticles, consequently leading to the killing of the cancerous cells without affecting non 
cancerous HUVECs and MCF10a providing a platform for the development of a non-invasive 
cancer treatment without any harmful side effects. The EIS was used to monitor the real-time 
consequences on cellular viability and a noticeable decrease in the growth profile of the MCF7 was 
observed with the application of the HER2-AuNPs and the electric fields indicating specific in-
hibitory effects on dividing cells in culture. To further understand the effects of the externally 
applied field to the cells, an Annexin V/EthD-III assay was performed to determine the cell death 
mechanism indicating apoptosis. The zeta potential of the SKOV3 and the MCF7 before and after 
incorporation of the HER2-AuNPs was also obtained indicating a decrease in zeta potential with 
the incorporation of the nanoparticles. The outcome of this research will improve our funda-
mental understanding of the behavior of cancer cells and define optimal parameters of electro-
therapy for clinical and drug delivery applications. 
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Introduction 
The effects of exogenous electric fields on physi-
ology and their possible relationship to diseases have 
interested researchers for years [1-3]. In 1855, Guil-
laume Duchenne discovered that alternating current 
leads to electrotherapeutic triggering of muscle con-
tractions thus spurring the use of electrical energy as 
medical treatment. Since then, the use of electric fields 
has become popular in fields such as gene and cellular 
therapies [4-6], and has even progressed to clinical 
trials for drug delivery [7], however; still little is 
known how electric fields may interact with intracel-
lular signaling pathways to potentially alter cell 
physiology.  
The idea of classifying cancers by their electrical 
properties was first proposed by Fricke and Morse in 
1926 [8]. Recently, there has been interest in the use of 
electrotherapy as a non-surgical and minimally inva-
sive treatment for cancer, since the electrical and 
physical properties of cancer cells differ from normal 
proliferating cells. Electrical properties of cells deter-
mine most of the cellular functions, predominantly 
proliferation and differentiation. In particular, the 
transmembrane potential, the voltage difference 
across the membrane produced by the balance of in-
tracellular and extracellular ionic concentrations, is 
responsible for controlling mitosis, DNA synthesis, 
and the majority of other cell cycle phenomena [9]. 
Several studies have previously been done to derive 
the relationship between transmembrane potential 
and cell proliferation. Initially, Cone and Tongier 
(1973) investigated the effects of transmembrane 
modification on the mitotic activity of Chinese ham-
ster ovary cells [10]. Their study showed that de-
creasing the cells transmembrane potential ultimately 
stopped the mitotic process in the cells with the pro-
cess being reversible once the transmembrane poten-
tial returned to a normal value. More recently, MCF-7, 
human adenocarcinoma, membranes have been 
shown to hyperpolarize during the G0/G1 phase of 
proliferation [11]. Manipulation of these electrical 
properties may provide a powerful electrotherapy 
option for the treatment of cancer as cancerous cells 
have been shown to have more electronegative 
membrane potential than normal proliferating cells, 
thus, further studies on cancer electrotherapy is war-
ranted.  
Current treatments for cancer have much poten-
tial; however, a major limitation in these treatments is 
the negative side effects that occur. Electrotherapy for 
cancer treatment is very promising alternative as it 
eliminates the toxic chemicals and possible immuno-
genic responses in the host tissue. Current research for 
cancer electrotherapy mostly focuses on using short 
electric pulses to alter cell physiology, in particular, 
the permeabilization of the cell membrane. This phe-
nomenon is then modified either by the addition of 
chemotherapy agents [12], by inducing apoptosis of 
the cells [13] or even for DNA vaccination against 
certain cancer types [14-15]. However, there are limi-
tations with this technique as it can only be efficient if 
all tumor cells are permeabilized, and thus there is 
also a size dependence of the tumor as smaller tumors 
show a higher response rate to the therapy [16]. Also, 
the electric field has to be as low as possible to ensure 
the safety of the procedure to prevent unwanted side 
effects such as erythema, edema, superficial epider-
mal erosion, or scars [12]. 
Previously, an electrical impedance sensor (EIS) 
was used to explore the responses of cancerous 
SKOV3 cells and normal HUVEC cells to low intensity 
(<2 V/cm) AC electric fields, determining that the 
optimal frequency for SKOV3 proliferation arrest was 
200 kHz, without harming the non-cancerous HU-
VECs [17]. A slower proliferation rate was observed in 
the cancer cells through the lower resistance curves of 
the EIS in real-time as the external field was applied 
compared to a control with no applied field (Scheme 
1/Figure 8). In this study, we determined if the effects 
of the externally applied electric field are cell type 
dependant using human breast adenocarcinoma cells 
(MCF7). The MCF7, along with non cancerous 
MCF10a, were subjected to the range of frequencies 
(50 kHz–2 MHz) similar to the previously tested 
SKOV3 and HUVEC to determine the optimal fre-
quency that would most hinder the proliferation of 
the MCF7. Monitoring the behavior of different types 
of cancerous cells under the effects of the electric field 
can lead to specific treatment paradigms for various 
types of cancers. 
The ultimate fate of these cells after they endure 
the effects of the applied field is the next focus of this 
study. Nanomaterials are being considered in the de-
velopment of new drugs and new therapies for dis-
ease control and improving the quality of life [18-20]. 
More recently, nanomaterials have been used in tissue 
engineering and medical imaging, leading to im-
proved diagnostics and new therapeutic treatments 
[21-23]. Nanoparticles have been extensively studied 
for use in biomedical applications, particularly gold 
nanoparticles (AuNPs), due to their low cytotoxicity 
[24], specifically for use in antibody targeted drug 
delivery to cells [25]. For example, HER2, human ep-
idermal growth factor receptor 2, is a cell membrane 
surface-bound receptor tyrosine kinase that is re-
sponsible for intracellular signal transduction and 
ultimately cell growth and differentiation [26]. HER2 
over-expression leads to cancerous cell proliferation 
and is seen in cancers such as breast cancer, ovarian 
cancer, stomach cancer, and even lung cancer [27], 
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and both SKOV3 and MCF7 cells over-express HER2 
markers on their surface membrane. It has also been 
shown that in the presence of an electric field, AuNPs 
could change the distribution of the field within the 
cell’s cytoplasm resulting in an inward net electric 
force which potentially could change the function of 
the cell [28]. Thus, further experiments specifically 
targeting the two types of cancer cells using HER2 
antibody functionalized gold nanoparticles 
(HER2-AuNPs) were performed to determine if en-
hanced electric field strength can be induced via the 
application of nanoparticles, consequently leading to 
the killing of the cancerous cells without affecting non 
cancerous HUVECs and MCF10a providing a plat-
form for the development of a non-invasive cancer 
treatment without any harmful side effects. 
The EIS was used to monitor the real-time con-
sequences on cellular viability under the electric field 
with the incorporation of the HER2-AuNPs. The 
binding of charged nanoparticles to the cell surface 
plasma membrane will change the zeta potential val-
ue of the cells, a feature of the cell that has been used 
in cell biology to study cell adhesion, activation, and 
agglutination based on cell-surface-charge properties 
[29]. Thus the zeta potential of the AuNPs, 
HER2-AuNPs and each cell type before and after in-
corporation of the HER2-AuNPs was taken to monitor 
this phenomenon. The HER2-AuNPs would bind to 
the HER2 receptors on the membrane of the cancer 
cells, thus affecting the cells’ zeta potential potentially 
producing a larger effect of cell viability of the can-
cerous cells with the application of the electric field to 
the combination of HER2-AuNPs and cell. The cell 
death mechanism was also tested by using an An-
nexin V/EthD-III assay to determine if the cells un-
dergo apoptosis or necrosis after the application of the 
applied electric field.  
Experimental Details 
Cell culture 
According to the American Cancer Society, every 
year over 200,000 American women are diagnosed 
with breast cancer, thus MCF7, human breast adeno-
carcinoma were chosen as another type of cancer cell 
for comparison with the SKOV3. HTB-77™ (SKOV3) 
and CRL-1730™ (HUVEC) cells were purchased from 
American Type Culture Collection (ATCC, Rockville, 
MD, USA) and were cultured in McCoy’s 5A Modi-
fied Medium and Dulbecco’s Modified Eagle Medium 
respectively, each containing 10 % fetal bovine serum, 
0.3 mg ml−1 L-glutamine, 100 U ml−1 penicillin and 100 
mg ml−1 streptomycin. The HTB-22™ (MCF7) and 
CRL-10317TM (MCF10a) were graciously donated 
from the Research Institute at Miami Children's Hos-
pital, Miami, FL, and were both cultured in Eagle's 
Minimum Essential Medium containing 10 % fetal 
bovine serum, 0.3 mg ml−1 L-glutamine, 100 U ml−1 
penicillin and 100 mg ml−1 streptomycin. The cell 
cultures were placed in an incubator (37 °C, 5 % CO2 
atmosphere) for 24 hours prior to the experiment so 
that the cells reached confluency with a final concen-
tration of 105 cells ml−1. 0.4 ml of cell suspension was 
inoculated into each well in the EIS chip for the ex-
periments.  
Electrical impedance sensing (EIS) 
The EIS chip design was previously reported 
[25]. In short, individual tissue culture wells of vol-
ume 9 × 9 × 10 mm3 are placed over an array of eight 
detecting gold electrodes (250 μm in diameter) each 
linked to a gold counter electrode (7 × 46 mm2).  
Application of external electric field 
The design of the application of the external 
electric field to the EIS chip was previously described 
[17]. In brief, a unique system of a pair of insulated 
wires (BLK KYNAR 100’, conductor area 0.25 mm) 
was designed to be placed in conjunction with the 8 
well array design of the EIS chip. The wires were 
placed in 4 of the wells with the other 4 wells used as 
the control. The wires were placed 1mm apart to al-
low spacing to encompass the whole electrode area. A 
Leader LFG-1300S Function Generator was used to 
provide the square AC waves at the desired frequen-
cies. 
Synthesis of AuNPs 
Hydrogen tetrachloroaurate (HAuCl4) (40 ml, 1.0 
mM) was added to an Erlenmeyer flask (250 ml), 
stirred and brought to the boil on a hotplate. Triso-
dium citrate (Na3C6H5O7) (4 ml, 1%) was added to the 
boiling solution. Three minutes after the addition of 
trisodium citrate, and 10 minutes of stirring, AuNPs 
were formed. The size of the AuNPs was character-
ized by the Zetasizer (Malvern Instruments, Wood-
stock, GA) and TEM and found to be 20 nm, the size 
indicated in the HER2 functionalization procedure. 
HER2 antibody functionalization of AuNPs 
The HER2 antibody preparation was done fol-
lowing the procedure of Zhu et al. [30]. In short, The 
AuNPs solution was concentrated 5X and the pH of 
the AuNPs solution for antibody labeling was ad-
justed to pH 8.5 ~ 9.0 with 0.2 ml of K2CO3 (0.1 M). 
Purified Anti-ErbB2/Her2 Monoclonal Antibody (5 
μl, 1 mg ml-1) was added to the AuNPs solution (750 
μl, 5X) and stirred gently at room temperature for 1 h. 
The conjugate was stabilized by adding BSA (90 μl, 
10%) in sodium borate (20 mM) for a final concentra-
tion of 1% and the solution was incubated for another 
 Theranostics 2014, Vol. 4, Issue 9 
 
http://www.thno.org 
922 
15 min. The mixture was then centrifuged at 7000 rcf 
for 15 min. Two phases can be obtained: a clear to 
pink supernatant of unbound antibodies and a dark 
red, loosely packed sediment of the AuNPs-Antibody 
conjugates. The supernatant was discarded and the 
pellet was resuspended in BSA/PBS (100 μl, 1%). Af-
ter another centrifugation at 7000 rcf for 15 min, the 
supernatant was removed and the pellet was resus-
pended in 100 μl buffer, containing sodium phosphate 
(20 mM), Tween 20 (0.25%), sucrose (10%), and BSA 
(5%). The conjugate was stored at 4° C until required 
for use. 
Apoptosis / Necrosis Assay 
Apoptotic/Necrotic Cells Detection Kit was 
purchased from PromoKine (Germany). The kit con-
tains FITC-Annexin V in TE buffer containing 0.1% 
BSA and 0.1% NaN3 (pH 7.5), EthidiumHomodimer 
III (EthD-III) in PBS and 5X Binding Buffer. A 1:5 di-
lution of Binding Buffer to DI water was made. After 
runs with the EIS, the cells were detached from the 
wells on the chip with 0.25% Trypsin/EDTA and 
suspended with the 1:5 Binding Buffer/DI solution 
giving a final concentration of 105 cells ml−1. 100 μl of 
the cell suspension was placed in a microcentrifuge 
tube to which 5 μl of FITC-Annexin V and 5 μl of 
EthidiumHomodimer III solutions were added to 
each tube. The samples were incubated at room tem-
perature for 15 minutes in the dark, after which the 
cells were washed and resuspended with the 1:5 
Binding Buffer/DI solution. Fluorescence intensity 
was determined using a confocal microscope (Perkin 
Elmer UltraViewVox system, USA) with FITC and 
Texas Red filter sets. 
Zeta potential measurement 
The ZetasizerNano ZEN 3600 (Malvern Instru-
ments, United Kingdom) was used to measure the 
zeta potential of the AuNPs, HER2-AuNPs and the 
HER2-AuNPs with each cell type, SKOV3, HUVEC, 
MCF7 and MCF10a. 
AFM imaging and analysis 
AFM images of live cells were obtained in fluid 
tapping mode using a Nanoscope IIIa multimode 
system (Veeco Metrology, CA). The cells were grown 
to confluency on Poly-L-Lysine coated glass co-
verslips. The AFM cantilever was positioned on four 
different regions of the cell surface to acquire 5 µm × 5 
µm topographical and amplitude images. Qualitative 
analysis of the particles was performed by visualiza-
tion of the amplitude and topographical images and 
by quantitative analysis of roughness measurements 
from the topographical images. Roughness values of 
the cell surface were calculated from the topograph-
ical image in an offline mode using Nanoscope Image 
Analysis software (Version 5.13r1; Veeco Metrology). 
Average cell membrane surface roughness measure-
ments were obtained at various time points repre-
senting characteristics of the cell surface influenced by 
NP attachment and internalization. A series of topo-
graphical images of SKOV3 cell surfaces were ob-
tained when the cells were incubated in the medium 
with and without AuNPs. 
Results 
Optimal frequency for MCF7 
As done before with the SKOV3 cells, the MCF7 
and MCF10 cells were subjected to five different fre-
quencies of alternating electric fields 50, 100, 150 and 
200 kHz and 2 MHz, to find the optimal frequency 
that would most hinder the growth of the MCF7 cells 
without harming the normal MCF10a cells. Figure 1 
shows the EIS results of the MCF10a (1 (a), (c)) and the 
MCF7 (1 (b), (d)) for the intermediate frequencies (100, 
150, 200) and the extreme frequencies (50 kHz, 2 MHz) 
respectively. 
The breast cancer cell lines behaved in a similar 
manner to the ovarian cancer cell lines tested previ-
ously as did the noncancerous MCF10a to the HU-
VECs. Under the influence of the electric field at all 
five frequencies, the resistance values for the MCF10a 
cells followed a trend of proliferating cells gradually 
attaching and spreading across the electrode surface 
creating an increase in resistance values. This can be 
seen in Figures 1 (a) and (c) which show the resistance 
values of the MCF10a when exposed to the interme-
diate range frequencies (100, 150, 200 kHz) and the 
extreme frequencies (50 kHz, 2 MHz) respectively. 
However, the MCF7 exhibited a variation of trends in 
resistance profiles with the different frequencies of the 
applied field. Shown in Figure 1 (b), 150 and 200 kHz 
decreased the resistance profiles of the MCF7, how-
ever, the MCF7 have the lowest resistance profile with 
100 kHz indicating the most affect on the cell prolif-
eration at this frequency. The extreme frequencies 
were also tested to justify that the intermediate fre-
quencies are the target frequencies suitable for cancer 
electrotherapy. The MCF10a cells retained a similar 
profile with the applied field as without (Figure 1 (c)). 
In Figure 1 (d), the MCF7 show more of a difference 
when the extreme frequencies are applied compared 
to the previously tested SKOV3. The higher frequency 
of 2 MHz had an effect on the MCF7 proliferation as 
can be seen in the lower resistance profile compared 
to the control with no field applied. This could be due 
to the more sensitive membrane of the MCF7 com-
pared to that of the other types of cancer cells. Cancer 
cells, in general, have lower membrane potentials 
with lower stiffness compared to their normal coun-
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terparts. This is seen in the Young’s modulus of each 
type of membrane using atomic force microscopy 
(AFM) [31]. In addition, the MCF7 breast cancer cells 
in general, were observed to have a lower Young’s 
modulus in comparison with other types of cancer 
cells, potentially giving the cells a weaker membrane. 
50 kHz also slowed down the proliferation of the 
MCF7 cells; however, the 100 kHz affected the prolif-
eration of these cells the most. 
 Digital images of the cells were also taken for the 
MCF10a and MCF7 cells with and without exposure 
of the 100 kHz applied field. This was done to get a 
visual understanding of the cell behavior on the EIS 
electrode surface as the electric field is applied. The 
changes in resistance profiles of the cells with and 
without the applied field could be due to a slower 
proliferation rate caused by the exposure to the field, 
or simply, by the detachment of the cells from the 
electrode. Figure 2 shows one well each of the 
MCF10a cells after 20 hours without the applied field 
(a), after 20 hours with the applied 100 kHz field (c), 
the MCF7 cells after 20 hours without the applied 
field (b), and after 20 hours with the applied 100 kHz 
field (d). We see the MCF10a maintain a solid mono-
layer over the electrode after 20 hours of field expo-
sure. However, for the MCF7, we do not see a solid 
monolayer attached over the electrode. In the case of 
cell detachment, there would be evidence of the de-
tached cells floating in the surrounding media, thus 
indicating the externally applied field having a det-
rimental affect towards the cell proliferation.  
HER2-AuNPs targeted enhancement 
Gold nanoparticles are being use in targeted 
therapies in biomedical engineering such as gene and 
drug delivery transfection vectors, DNA-binding 
agents and in various imaging systems due to their 
inert properties [32]. In this study, we functionalized 
our AuNPs with a HER2 antibody for a targeted de-
livery of the particles to the cell membrane since 
HER2 is overexpressed in both breast and ovarian 
cancers, and based on the length of the experiment, 
the AuNPs were assumed to remain on the membrane 
surface during this experiment. We tested the two 
types of cancer cells, SKOV3 and MCF7, as well as the 
non cancerous HUVECs and MCF10a, under their 
respective optimal frequencies, 200 and 100 kHz, with 
and without the integration if the HER2-AuNPs to 
determine any enhancement in the effects of the ap-
plied electric field.  
 
Figure 1. Resistance values of MCF10a (a) and MCF7 (b) under electric fields of frequencies 100, 150 and 200 kHz. No apparent effect was noticed for the normal 
MCF10a, however, a significant decrease in resistance values was observed for the MCF7 for all three frequencies. 50 kHz and 2 MHz frequencies were tested on both 
MCF10a (c) and MCF7 (d). The MCF10a showed no apparent effect on the cell proliferation as seen in the similar resistance curves to the control. 100 kHz showed 
the largest decrease out of all the frequencies for the MCF7. 
 Theranostics 2014, Vol. 4, Issue 9 
 
http://www.thno.org 
924 
 
Figure 2. MCF 10a cells after 20 hours without the applied field (a), after 20 hours with the applied 100 kHz field (c), the MCF 7 cells after 20 hours without the 
applied field (b), and after 20 hours with the applied 100 kHz field (d). We see the MCF 10a maintain a solid monolayer over the electrode after 20 hrs of field 
exposure. However, for the MCF 7, we do not see a solid monolayer attached over the electrode indicating a decrease in cell proliferation. In the case of cell 
detachment, there would be evidence of the detached cells floating in the surrounding media. 
 
The first concern with using the metallic nano-
particles under the applied electric field would be the 
potential heating of the nanoparticles. AuNPs are be-
ing used for cancer hyperthermia studies [33], how-
ever, these studies use nearinfrared (NIR) laser light, 
[34] radiowaves, [35] or even ultrasound [36]. To 
make sure temperature would not be a factor for the 
cancer cells under the intermediate frequencies de-
termined for the two types of cancer cells, we tested 
the temperature of the wells at incremental times of 6 
hours for the SKOV3 and 4 hours for the MCF7 for an 
entire run. Figure 3 (a) and (b) shows the average 
temperature of the 8 wells on one chip for the SKOV3 
and the MCF7, respectively. Here we do not see any 
significant change in the tested temperatures when 
the HER2-AuNPs were incorporated for either type of 
cell, indicating no apparent thermal effects from the 
nanoparticles. Figure 4 (a) and (c) shows the resistance 
values obtained for the noncancerous HUVECs and 
MCF10a, respectively. As in the previous experiment, 
there is no noticeable change in the resistance values 
when the electric field was applied to the cells com-
pared to the control cells with now applied field. Also, 
with the incorporation of the HER2-AuNPs, there is 
still no apparent effect in the resistance profiles. 
However, a noticeable decrease in the growth profiles 
of the SKOV3 and MCF7 was observed with the ap-
plication of the HER2-AuNPs and the electric fields 
compared to just the field itself indicating specific 
inhibitory effects on dividing cells in culture (Figure 4 
(b) and (d)).  
Gold nanoparticles with sizes ranging from a 
few nanometers up to one hundred nanometers are 
most commonly used for study cell-nanoparticle in-
teractions. To achieve effective targeting, the HER2 
antibody functionalized AuNPs with a series of sizes 
are tested. Transmission electron microscopy (TEM) 
analysis, AFM, and the Zetasizer (Malvern Instru-
ments, Woodstock, GA) were performed for the de-
termination of particle sizes. Over 100 particles were 
counted in multiple pictures from different areas of 
the TEM grid resulting a size variation of ±10%. The 
detail of nanoparticle preparation and characteriza-
tion can be found in our previous publication (17, 
46-48). We found that the antibody functionalized 
AuNPs in the size range from 10 to 30 nm covered cell 
surface more uniformly and efficiently than the parti-
cles outside this range. Instead of casting cell surface, 
particles with size bigger than 30 nm are found to be 
more easily entering cells via endocytosis process 
leading to less effect on cells upon electrical field 
stimulation.  
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Figure 3. Average temperature readings for the 8 wells on a chip at various time points throughout an EIS run for SKOV3 (a) and MCF7 (b). 
 
Figure 4. Resistance values for HUVECs (a), SKOV3 (b), MCF10a (c) and MCF7 (d) under the effects of the optimal frequencies (SKOV3 200 kHz, MCF7 100 kHz) 
with and without the application of HER2-AuNPs. 
 
AFM characterization in wet condition was 
conducted to observe the nanoparticle-cell interaction 
by quantitative analysis of the roughness of cell 
membrane upon nanoparticle exposure. Time-lapsed 
(1, 3 and 24 hours) AFM amplitude images were per-
formed on the cells treated with and without HER2 
antibody modified AuNPs. From the amplitude im-
ages it is clear that the cells treated with HER2 anti-
body showed higher number of AuNPs attached on 
the cell surface when compared to the 
non-functionalized AuNPs. Compared to the rough-
ness of cell membrane exposed to the normal AuNPs 
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(Figure 5b), the higher roughness (Figure 5a) of upon 
exposure by antibody modified AuNPs indicating the 
specific binding of functionalized nanoparticles to the 
cell surface. The HER2 antibody functionalized parti-
cles clearly specifically bind to the HER2 receptors on 
the membrane of cancer cells.  
Amplitude images obtained at 24 hours (Figure 
5c) showed that upon HER2-AuNPs exposure, there 
was a significant number of particles present on the 
cell surface, indicating that the antibody functional-
ized AuNPs remained on the cell membrane surface 
during this experiment.  
Apoptosis / Necrosis Assay 
Apoptosis and necrosis are the two major pro-
cesses leading to cell death. Apoptosis is the process 
of programmed cell death caused by a cascade of bi-
ochemical signals within the cell and can be triggered 
from a variety of external factors usually in the form 
of stress towards the cell. In the case of apoptosis, the 
cell prepares itself by performing changes within, one 
of them being changes in the phospholipid content of 
the cell membrane.  
Apoptotic cells can be easily identified with the 
protein Annexin V, which is binds to phosphatidyl-
serine, a protein located in the cell membrane. Under 
normal circumstances, the phosphatidylserine is 
found in the inner layer of the cell membrane double 
layer. In the early stages of apoptosis, these phospha-
tidylserine proteins move to the outer layer of the 
membrane where Annexin V labeled with fluorescein 
(FITC) can bind, staining apoptotic cells green.  
Necrosis is a traumatic cell death that results 
from any acute damage caused to the cell where the 
cell membrane integrity is compromised. This results 
in the cytosol and organelles within the cell to spill 
into the surrounding environment. Ethidiumho-
modimer III (EthD-III) is a highly positively charged 
nucleic acid probe which binds to DNA, thus is used 
to classify necrotic cells by staining them with red 
fluorescence.  
To further understand the effects of the exter-
nally applied field to the cells, an Annexin V/ 
EthD-III assay was performed to determine the cell 
death mechanism with green fluorescent membrane 
staining indicating apoptotic cells, and red fluorescent 
nuclear staining necrotic cells. Figure 6 shows the 
fluorescent staining of MCF7 cells from one well after 
20 hours of exposure to 100 kHz electric field. The 
image on the left shows EthD-III stained cells (ne-
crotic) and the image on the right shows Annexin V 
stained cells (apoptotic). There are significantly more 
cells stained with the Annexin V indicating the death 
mechanism triggered from the applied electric field to 
be apoptosis. 
 
Figure 5. AFM amplitude images showing the surface topography of SKOV-3 cell membrane after treating with and without HER2 modified –AuNPs for 3 hours. It 
is to be noted that the cells treated with HER2 modified –AuNPs (a) showed more number of particles on the cell surface than the cells treated non modified NPs 
(b). Figure 5C showing the surface topography of SKOV-3 cell membrane after treating with HER2 modified –AuNPs for 24 hours.  
 
Figure 6. Fluorescent staining of MCF7 cells after 20 hours of exposure to 100 kHz electric field. The image on the left shows EthD-III stained cells (necrotic) and 
the image on the right shows Annexin V stained cells (apoptotic).  
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Zeta Potential Measurements  
Due to electrostatic forces, the interior of the cell 
has uniform potential and a voltage drop across the 
plasma membrane. With the application of any ex-
ternal electric field, the first electrostatic force en-
countered would be the membrane potential. Can-
cerous cells have been shown to have lower cell and 
cytoplasmic conductivity as well as a lower mem-
brane capacitance compared to non-cancerous cells 
[37]. This outermost electrically negative zone is 
composed of negatively charged sialic acid molecules 
found on the tops of glycoproteins extending outward 
from the cell membrane. The zeta potential, the po-
tential that exists at the electrical double layer of a 
particle or cell, is created from these sialic acid resi-
dues. Cancer cells have significantly more sialic acid 
molecules and thus a greater surface negativity. Thus, 
any external factor that would affect these residues 
would change the surface negativity of the cell. 
In 1990, Seeger and Wolz correlated the electro-
negativity of cancer cell membranes with membrane 
degeneration throughout the process of carcinogene-
sis [38]. This process involves the degradation of the 
external cell membrane initially, causing more per-
meability to water-soluble substances to potassium, 
magnesium, and calcium migrate from the cells and 
sodium and water accumulate in the cell interior. This 
is then followed by degenerative changes in the inner 
membrane of the mitochondria causing loss of an-
chorage of critical mitochondrial enzymes. Since the 
membrane potential in a cancer cell is lower than the 
membrane potential of a healthy cell, the electrical 
field across the membrane of a cancer cell is reduced. 
The reduction in membrane electrical field strength 
will in turn cause alterations in the metabolic func-
tions of the cell. 
In order to understand the effects of the applied 
electric field with targeted nanoparticle enhancement, 
the next focus of the study was to observe the zeta 
potential of the cells before and after exposure to the 
nanoparticles. Zeta potential is the electrostatic po-
tential near the surface of a particle and usually this 
surface charge is counterbalanced by charges of op-
posite sign in the surrounding solution. With the na-
noparticles, once in contact with the cell membrane, 
the surface charges of the particles may affect the cells 
membrane properties with negatively charged ions or 
molecules will decrease and positively charged ions 
will increase the surface zeta potential of the cell 
[39-40], thus attachment of negatively charged nano-
particles on the cell’s membrane will cause its zeta 
potential to become more negative.  
We measured the zeta potential of our AuNPs 
before and after functionalization with the HER2 an-
tibody to see if the antibody would affect the nano-
particles’ zeta potential. We then measured the zeta 
potential of the two cancer cell lines, SKOV3 and 
MCF7, with and without the incorporation of the 
HER2-AuNPs and compared the results to those for 
the non cancerous cell lines, HUVEC and MCF10a, 
respectively (Figure 7). In all cases, the bare AuNPs 
had the lowest zeta potentials with values of -37.4 ± 
0.7, -40.0 ± 0.05, -43.3 ± 0.7, and -39.3 ± 0.4 as shown in 
Figure 7 (a), (b), (c) and (d), respectively. With the 
functionalization of the HER2 antibody, the zeta po-
tentials increased slightly for each case (-30.5 ± 1.4, 
-37.1 ± 1.2, -41.6 ± 1.0, -35.5 ± 0.6). The cells themselves 
had initial zeta potentials of -19.2 ± 0.9 (HUVEC), -19.3 
± 0.8 (SKOV3), - 20.5 ± 0.9 (MCF10a) and -28.3 ± 1.3 
(MCF7). After incubation with the HER2-AuNPs, the 
cancerous cell showed a significant decrease in zeta 
potentials compared to the non-cancerous cells. For 
the HUVECs, the zeta potential slightly increased to 
-18.3 ± 0.9, and the MCF10a also showed a slight in-
crease to -18.9 ± 2.3.(Figure 7 (a), (c), respectively). The 
case was different for both cancerous cell types as the 
zeta potentials dropped after HER2-AuNPs function-
aliztion for the SKOV3 to -25.3 ± 1.3, and for the MCF7 
to -37.6 ± 1.3 (Figure 6 (b), (d), respectively).  
Discussion 
The cell membrane provides a barrier for the cell 
and its surroundings and as a result is the first line of 
defense for the cell to survive. The membrane controls 
the exchange of electrically charged ions across the 
cell membrane thus creating the cell membrane po-
tential. It is this potential that is the underlying char-
acteristic of the cell that could distinguish between 
normal and cancerous cells. It was been noted before 
that cancerous cell have a lower membrane potential, 
and it has been shown that the cell’s membrane 
changes during cancer transformation, in particular 
the membrane’s fluidity and charge [41-42]. There-
fore, by altering the cell membrane potential, one 
could possibly control the fate of the cell. 
Cancerous cell membranes have a higher num-
ber of negatively charged sialic acids, which regulate 
intercellular contacts and the interaction of charged 
macromolecules with the cell surface [43]. It is the 
number of sialic acids that lead to any cell’s overall 
negative membrane potential and ultimately deter-
mines a cell’s zeta potential [44]. Sialyation is one of 
the factors that cause the cancer cell membrane to be 
more electronegative and consequently, any factor 
that increases or decreases the number of sialic acid 
residues will change the degree of membrane nega-
tivity.  
 We had proposed that gold nanoparticles func-
tionalized with specific antibodies to target the cancer 
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cells would enhance the effects of the electric field 
towards the cells without affecting the non-cancerous 
cells due to the different membrane properties of the 
cancerous cells. In our study, the antibody used tar-
geted HER2 glycoprotein receptor on the cell mem-
brane. Since sialic acids are generally found at the end 
of most glycoproteins, and the specific cancer cells 
tested overexpress the HER2 receptor, we can deduce 
that there would be more HER2-AuNPs attracted to 
the cancer cells as opposed to the regular cells (Figure 
8).  
With more negatively charged HER2-AuNPs 
attached to the cancer cell membrane, the cell mem-
brane could more vulnerable to the affects of the ex-
ternal electric field due to the decrease in surface 
charge. An important consequence of the existence of 
electrical charges on the surface of particles is that 
they will exhibit certain effects under the influence of 
an applied electric field. Since the changes in zeta po-
tential values depend on cell surface charge, nano-
particle surface charge and their interaction we ob-
served a decrease in zeta potentials of the cells after 
nanoparticle incorporation leaving the cells more 
vulnerable to the detrimental effects of the applied 
electric field. 
There was also a noticeable difference in the be-
havior between the two types of cancer cells. The 
breast cancer cell line, MCF7 was affected by a lower 
frequency than the ovarian cancer cell line, SKOV3. 
This could be due to the MCF7 having a more simpli-
fied cytoskeleton compared with MCF10A, which 
results in less stiffness and easier deformation [45]. 
Conclusion 
Cancer electrotherapy treatments are showing 
considerable promise to avoid the negative side ef-
fects of traditional cancer treatments such as chemo-
therapy. We previously demonstrated that cancer cell 
proliferation is affected by externally applied alter-
nating electric fields in the intermediate frequency 
range of 100 kHz – 200 kHz. In this study, we 
demonstrated that different types of cancer cells are 
affected by different optimal frequencies of these 
electric fields. To further understand the effects of the 
applied fields on the cells, we performed an Annexin 
V/ EthD-III assay to conclude the fate of the cells as 
apoptosis. We also observed a decrease in prolifera-
tion with the addition of HER2-AuNPs to target the 
cancer cells and enhance the effects of the electric field 
towards the cells without affecting the non-cancerous 
cells. With the attached nanoparticles, the zeta poten-
tial of the SKOV3 and the MCF7 before and after in-
corporation of the HER2-AuNPs decreased compared 
to their non-cancerous counterparts. The decrease in 
membrane potential would thus leave the cells more 
vulnerable to the detrimental effects of the applied 
electric field. The outcome of this research will im-
prove our fundamental understanding of the behavior 
of cancer cells and define optimal parameters of elec-
trotherapy for clinical and drug delivery applications.  
 
 
Figure 7. Zeta potential values for HUVECs (a), SKOV3 (b), MCF10a (c), and MCF7 (d). With the integration of the HER2-AuNPs, the zeta potential of both cancer 
cells decreased in comparison to the two noncancerous cell types. 
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Figure 8. Schematic representation of the cells with and without HER2-AuNPs coating in the field of electrical stimulation. 
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